Daohong Zhou

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Venues

The Journal of experimental medicine

Nature communications

Journal of hematology & oncology

Aging cell

University of Florida

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Florida Mar 01 2018

United States

Professor :: Pharmacodynamics

Publications

Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Kristin A Altwegg, Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu, Junhao Liu, Uday P Pratap, Behnam Ebrahimi, John R Sanchez, Xiaonan Li, Shihong Ma, Ben Ho Park, Bindu Santhamma, Yidong Chen, Zhao Lai, Ganesh V Raj, Yaxia Yuan, Daohong Zhou, Gangadhara R Sareddy, Rajeshwar R Tekmal, Stanton F McHardy, Tim Hui-Ming Huang, Manjeet K Rao, Hariprasad Vankayalapati, Ratna K Vadlamudi
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer. Cancer research 82 (20) (2022)
Dong-Wen Lv, Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang, Wanyi Hu, Jing Pei, Qi Zhang, Shuo Zhou, Sajid Khan, Xuan Zhang, Nan Hua, Qingping Yang, Sebastian Arango, Weizhou Zhang, Digant Nayak, Shaun K Olsen, Susan T Weintraub, Robert Hromas, Marina Y Konopleva, Yaxia Yuan, Guangrong Zheng, Daohong Zhou
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature communications 12 (1) (2021)
Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature communications 12 (1) (2021)
Myung-Chul Kim, Nicholas Borcherding, Kawther Khalid Ahmed, Andrew P Voigt, Ajaykumar Vishwakarma, Ryan Kolb, Paige N Kluz, Gaurav Pandey, Umasankar De, Theodore T Drashansky, Eric Y Helm, Xin Zhang, Katherine N Gibson-Corley, Julia Klesney-Tait, Yuwen Zhu, Jinglu Lu, Jinsong Lu, Xian Huang, Hongrui Xiang, Jinke Cheng, Dongyang Wang, Zheng Wang, Jian Tang, Jiajia Hu, Zhengting Wang, Hua Liu, Mingjia Li, Haoyang Zhuang, Dorina Avram, Daohong Zhou, Rhonda Bacher, Song Guo Zheng, Xuefeng Wu, Yousef Zakharia, Weizhou Zhang
CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nature communications 12 (1) (2021)
Yong-Han He, Wen Li, Dong-Wen Lv, Xin Zhang, Xuan Zhang, Yuma T Ortiz, Vivekananda Budamagunta, Pierre-Yves Desprez, Guangrong Zheng, Daohong Zhou
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging cell 19 (3) (2020)
Yong-Han He, Xuan Zhang, Jianhui Chang, Ha-Neui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dong-Wen Lv, Lin Song, Wen Li, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Yuma T Ortiz, Vivekananda Budamagunta, Jennifer H Elisseeff, Judith Campisi, Maria Almeida, Guangrong Zheng, Daohong Zhou
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nature communications 11 (1) (2020)
Yonghan He, Sajid Khan, Zhiguang Huo, Dongwen Lv, Xuan Zhang, Xingui Liu, Yaxia Yuan, Robert Hromas, Mingjiang Xu, Guangrong Zheng, Daohong Zhou
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. Journal of hematology & oncology 13 (1) (2020)
Yonghan He, Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan, Dinesh Thummuri, Yuma T Ortiz, Xin Zhang, Dongwen Lv, Janet S Wiegand, Wen Li, Adam C Palmer, Guangrong Zheng, David M Weinstock, Daohong Zhou
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of hematology & oncology 13 (1) (2020)
Sajid Khan, Yonghan He, Xuan Zhang, Yaxia Yuan, Shaoyan Pu, Qing-Peng Kong, Guangrong Zheng, Daohong Zhou
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. Oncogene 39 (26) (2020)
Maria Almeida, Ha-Neui Kim, Li Han, Daohong Zhou, Jeff Thostenson, Ryan M Porter, Elena Ambrogini, Stavros C Manolagas, Robert L Jilka
Increased marrow adipogenesis does not contribute to age-dependent appendicular bone loss in female mice. Aging cell 19 (11) (2020)
Sajid Khan, Xuan Zhang, Dong-Wen Lv, Qi Zhang, Yonghan He, Peiyi Zhang, Xingui Liu, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Jing Pei, Weizhou Zhang, Abhisheak Sharma, Christopher R McCurdy, Vinitha M Kuruvilla, Natalia Baran, Adolfo A Ferrando, Yong-Mi Kim, Anna Rogojina, Peter J Houghton, Guangcun Huang, Robert Hromas, Marina Konopleva, Guangrong Zheng, Daohong Zhou
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature medicine 25 (12) (2019)

Daohong Zhou.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daohong Zhou